SAN ANTONIO (GenomeWeb) – In a randomized Phase II study, advanced breast cancer patients with BRCA mutations receiving AbbVie's PARP inhibitor veliparib in combination with platinum-based chemotherapy had better progression-free survival and overall survival compared to those receiving just chemo, but these improvements were not statistically significant.
Get the full story with
360Dx Premium
Only $95 for the
first 90 days*
360Dx Premium gives you:
✔ Full site access
✔ Interest-based email alerts
✔ Access to archives
Never miss another important industry story.
Try 360Dx Premium now.
You may already have institutional access!
Check if I qualify.
Already a 360Dx or GenomeWeb Premium member?
Login Now.
*Before your trial expires, we’ll put together a custom quote with your long-term premium options.